Compare Cognizant Technology Solutions Corp (CTSH) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Enveric Biosciences Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.71 (market cap $25.71B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Cognizant Technology Solutions Corp is far larger — about 3843× Enveric Biosciences Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.31% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Enveric Biosciences Inc for 14 Days on average.
| CTSH | ENVB | |
|---|---|---|
Market Cap | $25.71B | $6.69M |
Volume | 5,152,376 | 41,141 |
Sector | Technology | Health |
52-Week High | $86.70 | $10.80 |
52-Week Low | $38.73 | $1.27 |
Typical Hold Time | 57 Days | 14 Days |
Enterprise Value | $26.75B | -$1.60M |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 4.88% on the day, with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with a P/E of 12.25 and net income margin of 10.26%, while revenue grew to $21.11B in 2025. Analyst consensus is mixed with a $64.25 price target, and the company continues to gain recognition for AI-driven initiatives and workplace excellence.
CTSH presents a balanced outlook with undervalued metrics and strong cash flow, but faces headwinds from technical bearishness and competitive IT spending pressures. The upcoming Q3 2026 earnings on October 29, 2026, will be critical for confirming growth trajectory amid evolving AI integration strategies.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
